Fig. 3

ActRII and BMP ligands similarly repress myogenic markers in human myoblasts and differentiated human myotubes. (A) qPCR analysis of myogenic differentiation gene markers in ligand-treated myoblasts. Human myoblasts (iHUSKMDC) were stimulated with vehicle as a negative control or single 300 ng/ml dose of ActA, BMP7, or BMP9 for 24 h with downstream gene expression determined by qPCR (n = 4/treatment). Data are mean ± standard deviation (SD) from the mean. Asterisks indicate differences with the control. Statistical analyses were conducted with a One-way ANOVA. *p ≤.05; **p ≤.01; ***p ≤.001; ****p ≤.0001 compared to control. (B) Heatmap for muscle and bone marker gene expression profiles in ligand-treated human myotubes. ActRII and BMP ligands show similar transcriptional signature on myogenic markers (left). Primary human myotubes (HUSKMDC) stimulated as above were analyzed by qPCR for select genes (n = 5/treatment) (right). Data are mean ± standard deviation (SD) from the mean. Asterisks in the heatmap indicate significant differential expression between the control and the treatment. Asterisks in the bar plot indicate differences with the control group. Statistical analyses were conducted with a One-way ANOVA. *p ≤.05; **p ≤.01; ***p ≤.001; ****p ≤.0001 compared to control